Cibles, voies et molécules

25 novembre 2008

Auteurs : A. Méjean, T. Lebret
Référence : Prog Urol, 2008, 18, S173, suppl. S7


Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser






Vignot S., Soria J.C. Thérapies moléculaires ciblées. De la biologie aux applications cliniques  Paris: John Libbey (2008). 
Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 2007 ;  7 : 295-308 [cross-ref]
Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy J Natl Cancer Inst 2001 ;  93 : 1062-1074 [cross-ref]
Chong H., Vikis H.G., Guan K.L. Mechanisms of regulating the Raf kinase family Cell Signal 2003 ;  15 : 463-469 [cross-ref]
Eisenmann K.M., VanBrocklin M.W., Staffend N.A., Kitchen S.M., Koo H.M. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad Cancer Res 2003 ;  63 : 8330-8337
Wang H.G., Rapp U.R., Reed J.C. Bcl-2 targets the protein kinase Raf-1 to mitochondria Cell 1996 ;  87 : 629-638 [cross-ref]
Mita M.M., Mita A., Rowinsky E.K. Mammalian target of rapamycin: a new molecular target for breast cancer Clin Breast Cancer 2003 ;  4 : 126-137 [cross-ref]
Kodaki T., Woscholski R., Hallberg B., Rodriguez-Viciana P., Downward J., Parker P.J. The activation of phosphatidylinositol 3-kinase by Ras Curr Biol 1994 ;  4 : 798-806 [cross-ref]
Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers Science 2004 ;  304 : 554
Philp A.J., Campbell I.G., Leet C., Vincan E., Rockman S.P., Whitehead R.H., et al. The phosphatidylinositol 3’-kinase p85alpha gene is an oncogene in human ovarian and colon tumors Cancer Res 2001 ;  61 : 7426-7429
Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway J Clin Oncol 2004 ;  22 : 2954-2963 [cross-ref]
Nicholson K.M., Anderson N.G. The protein kinase B/Akt signaling pathway in human malignancy Cell Signal 2002 ;  14 : 381-395 [cross-ref]
de Graffenried L.A., Friedrichs W.E., Russell D.H., Donzis E.J., Middleton A.K., Silva J.M., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity Clin Cancer Res 2004 ;  10 : 8059-8067 [cross-ref]
Neuzillet Y., Karam G., Lechevallier E., Kleinclauss F. Comité Transplantation de l’Association Française d’Urologie [MTOR inhibitors: from transplantation to oncology. AFU 2006 Transplantation Committee Review of the literature] Prog Urol 2007 ;  17 : 928-933 [cross-ref]
Wiederrecht G.J., Sabers C.J., Brunn G.J., Martin M.M., Dumont F.J., Abraham R.T. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells Prog Cell Cycle Res 1995 ;  1 : 53-71 [cross-ref]
Calne R.Y., Collier D.S., Lim S., Pollard S.G., Samaan A., White D.J., et al. Rapamycin for immunosuppression in organ allografting Lancet 1989 ;  2 : 227 [cross-ref]
Hanahan D., Weinberg R.A. The hallmarks of cancer Cell 2000 ;  100 : 57-70 [cross-ref]
Schwartz G.K., Shah M.A. Targeting the cell cycle: a new approach to cancer therapy J Clin Oncol 2005 ;  23 : 9408-9421 [cross-ref]
Shah M.A., Schwartz G.K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy Clin Cancer Res 2001 ;  7 : 2168-2181


© 2008  Elsevier Masson SAS. Tous droits réservés.